Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.

Daniel PodzamczerArkaitz ImazAna Lopez-LirolaHernando KnobelMar MasiáChiara FanciulliCristina HernándezMaría LagardeAngela GutierrezAdrià CurranLuis MoranoMarta Montero-AlonsoJesús Troya GarcíaRaúl RigoMaría CasadellàAntonio Navarro-AlcarazFernando ArdilaMariona PareraEnrique BernalPatricia EcheverriaVicente EstradaCarmen Hidalgo-TenorioJuan MacíasPaula PrietoJoaquín PortillaEulalia ValenciaMaría Jesús VivancosAntonio Rivero

Published in: The Journal of antimicrobial chemotherapy (2023)

Our data suggest that BIC/FTC/TAF + darunavir/cobicistat is an effective, well-tolerated regimen that may improve convenience and, potentially, long-term success in stable heavily pre-treated PLWH.

Keyphrases

antiretroviral therapy
hiv infected patients
hiv infected
human immunodeficiency virus
hiv positive
hiv aids
electronic health record
big data
hepatitis c virus
data analysis